Aimmune Therapeutics will present the results of its Phase 2 continuation trial for its desensitization product for food allergies. The presentation will be made at the 2016 American Academy of Allergy, Asthma and Immunology’s annual meeting in Los Angeles by J. Andrew Bird, M.D., Assistant Professor, University of Texas Southwestern Medical Center.
The peanut allergy treatment has been undergoing American and European trials for efficacy with the latest clinical trial phase completing late last year. This second study followed a successful first study completed last year. The previous study found that the Aimmune treatment could give resistance in peanut allergic patients at a level equal to three or more peanut kernels (1,043 mg peanut protein).
AR101 efficacy and safety data from this latest ARC002 study will be presented in an oral abstract at AAAAI.
“Since we announced positive findings from our ARC002 Phase 2 follow-on trial late last year, we’ve been eager to share our full dataset with everyone who is tracking our progress,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “We’re excited to see our data presented to leading food allergy researchers and practitioners at the prestigious AAAAI meeting and to have the opportunity to contribute to further understanding of the potential of peanut allergy desensitization.”
The study’s results will be announced at the AAAAI meeting on March 6, 2016 in Los Angeles.